Britain's Immunodiagnostic Systems Holdings Plc said first-half revenue from continuing operations rose 56 percent and it was confident of executing its plans for the current year.
The maker of diagnostic testing kits also said overall trading remained in line with its expectations.
Turnover from continuing operations for the the six months ended Sept. 30 rose to 16.9 million pounds from 10.8 million pounds as revenue rose in all direct sales territories with substantial growth in the United States, France and Germany.
Sales of vitamin D products doubled compared to same period last year, it added.
Separately, the company said it signed an agreement with Technogenetics S.R.L. of Milan, a unit of Bouty Healthcare, broadening the scope of its existing agreement on developing its fully automated immunoanalyser, IDS-iSYS.
Shares of Immunodiagnostic closed at 407.5 pence on Friday on the London Stock Exchange. (Reporting by Ramkumar in Bangalore; Editing by Vinu Pilakkott)